

Supplementary materials to:

The Questionable Quality Profile of Food Supplements: The Case of Red Yeast Rice Marketed Products

Antonella Vitiello ^{1,†}, Luana Izzo ^{2,†}, Luigi Castaldo ², Ivana d'Angelo ³, Francesca Ungaro ¹, Agnese Miro ^{1,*}, Alberto Ritieni ² and Fabiana Quaglia ¹

¹ Drug delivery Laboratory, Department of Pharmacy, University of Naples Federico II, Via Domenico Montesano 49, 80131, Naples, Italy; antonella.vitiello3@unina.it (A.V.); francesca.ungaro@unina.it (F.U.); fabiana.quaglia@unina.it (F.Q.)

² FoodLab Laboratory, Department of Pharmacy, University of Naples Federico II, Via Domenico Montesano 49, 80131 Naples, Italy; luana.izzo@unina.it (L.I.); luigi.castaldo2@unina.it (L.C.); alberto.ritieni@unina.it (A.R.)

³ Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania "Luigi Vanvitelli", Via Antonio Vivaldi 43, 81100 Caserta, Italy; ivana.d'angelo@unicampania.it (I.d.A)

* Correspondence: agnese.miro@unina.it (A.M.); Tel.: +39 081678615

† These authors contributed equally to this work.

Table S1. Experimental condition and specification of mass uniformity assay prescribed by Ph. Eur. 11. Ed.

Dosage Form	Average Mass	Percent deviation
Tablets (uncoated and film-coated)	Not more than 80 mg	10
	More than 80 mg and less than 250 mg	7.5
	250 mg or more	5
Capsules	Less than 300 mg	10
	300 mg or more	7.5

Table S2. Experimental conditions and specification for pharmacopeial disintegration test.

European Pharmacopoeia 11		
Dosage form	Immersion liquid/disc	Maximum time of Disintegration
Uncoated tablets	Purified water (35-39°C) with disc	15 min
Coated tablets	Purified water (35-39°C) with disc ^a	30 min (film-coated)
		60 min (other coatings)
Gastro-resistant tablets	HCl 0.1 M (35-39°C) without disc and then	Intact after not less than 1h
	Phosphate buffer solution pH 6.8 (35-39°C) with disc ^b	60 min
Hard capsules	Purified water or HCl 0.1 M ^c	30 min
Soft capsules	Purified water or HCl 0.1 M with disc ^d	30 min

^a If any of the tablets has not disintegrated, the test is repeat on a further 6 tablets, replacing water R with 0.1 M hydrochloric acid.

^b If the tablets are not compliant to the test, due to disc adherence, the test should be repeated without discs.

^c The use of discs is required if the capsules float in the immersion liquid.

^d If the sof capsule adheres to the disc, it can be omitted.

Table S3. Stock solutions composition.

Salt solution	Stock concentration (mol/L)	SSF (pH 7)		SGF (pH 3)		SIF (pH 7)	
		mL of Stock added to prepare 0.4 L (mL)	Final salt concentration in sample (mmol/L)	mL of Stock added to prepare 0.4 L (mL)	Final salt conc. in sample (mmol/L)	mL of Stock added to prepare 0.4 L (mL)	Final salt conc. in sample (mmol/L)
KCl	0.5	15.1	15.1	6.9	6.9	6.8	6.8
KH ₂ PO ₄	0.5	3.7	1.35	0.9	0.9	0.8	0.8
NaHCO ₃	1	6.8	13.68	12.5	25	42.5	85
NaCl	2	-	-	11.8	47.2	9.6	38.4
MgCl ₂ (H ₂ O) ₆	0.15	0.5	0.15	0.4	0.12	1.1	0.33
NH ₄ (CO ₃) ₂	0.5	0.06	0.06	0.5	0.5	-	-
CaCl ₂ (H ₂ O) ₂	0.3	-	1.5	-	0.15	-	0.6

Abbreviations: SSF: simulated salivary fluid, SGF: simulated gastric fluid, and SIF: simulated intestinal fluid.

Table S4. Information relevant for the study reported on the label of FS.

Sample	Dosage form category	Single unit weight ^a (mg)	Number of AIs	AIs (Monacolin K) (mg)	Inactive ingredients (mg)
#1	Film-coated tablet	400	7	290 (-) ^d	110
#2	Film-coated tablet	1000	2	539 (1.45) ^b	471
#3	Film-coated tablet	1100	3	615 (10) ^b	385
#4	Film-coated tablet	1340	4	1004 (5) ^b	336
#5	Film-coated tablet	983	6	780 (-) ^c	203
#6	Uncoated tablet	1000	1	667 (-) ^d	333
#7	Uncoated tablet	550	5	320 (10) ^b	230
#8	Uncoated tablet	Not reported	8	739 (10) ^b	-
#9	Uncoated tablet	330	1	200 (10) ^b	130
#10	Hard shell capsule	450	2	238.7 (10) ^b	211
#11	Hard shell capsule	500	2	280 (10) ^b	220
#12	Hard shell capsule	450	6	213 (2.2) ^b	237
#13	Softgels	1600	8	1063 (10) ^b	537
#14	Softgels	1777	4	658 (5) ^b	1120

^a Calculated from the ratio between the total weight declared on the label and the number of dosage form units.

^b Reported on the label as monacolin K.

^c Reported on the label as monacolins.

^d Not specified.

AI= Active ingredient.

Note. Following COMMISSION REGULATION (EU) 2022/860, the use of monacolins from red yeast rice is allowed at levels of less than 3 mg per portion of the product recommended for daily consumption.

Table S5. Inactive ingredients listed on the RYR FS label.

		Film-coated tablets					Uncoated tablets			
		#1	#2	#3	#4	#5	#6	#7	#8 ^a	#9
Tablet/tablet core	Microcrystalline cellulose	X	X	X ^b	X ^b	X	X ^b	X	-	X ^b
	Starch						X		-	
	Maltodextrines from Maize		X						-	
	Calcium Carbonate						X		-	
	Cross-linked sodium carboxymethylcellulose		X	X	X	X			-	
	Silicon dioxide		X	X	X	X	X	X	-	X
	Magnesium salts of fatty acids	X ^c	X	X	X	X	X	X	-	X
	Carminic Acid				X				-	
	Titanium dioxide (E. 171) ^d		X	X					-	
	Iron oxide red			X					-	
Iron oxide black								-		
Coating	Iron oxides and iron hydroxides		X		X				-	
	Hydroxypropyl methyl cellulose	X	X	X					-	
	Hydroxypropylcellulose					X			-	
	Polyvinyl alcohol			X					-	
	Polyvinylpyrrolidone					X			-	
	Microcrystalline cellulose	X	X	X	X	X			-	
	Talc		X		X	X			-	
	Polyethylene glycol		X		X				-	
	Glycerol			X					-	
	Stearic acid	X							-	
Polysorbate 80				X				-		
Niacin (nicotinamide/vitamin B3)				X				-		
Shellac					X			-		

^a The label does not report the ingredient list.

^b Reported as “cellulose” in the ingredient list.

^c Reported as “vegetable magnesium stearate” in the ingredient list.

^d Banned in food since 7th August 2022.





Figure S1. Extracted ion chromatogram (a) and mass spectra (b) of citrinin